Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the…
$3.07-0.65%
报价 2026-11-16
市值
$771.7M
EV
$1.45B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -61.6%
$2.88$7.99
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-16不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ARDXArdelyx, Inc. | $771.7M | -0.6% | +20.5% | 90.3% | – | – | – | |
| SYRESpyre Therapeutics, Inc. | $9.44B | -4.5% | 0.0% | 0% | – | – | – | |
| PHVSPharvaris N.V. | $2.28B | -2.8% | – | 0% | – | – | – | |
| BCRXBioCryst Pharmaceuticals, Inc. | $1.92B | -2.1% | +16.0% | 97.7% | 7.8x | 7.0x | 5.5x | |
| TRVITrevi Therapeutics, Inc. | $1.89B | -2.6% | – | 0% | – | – | – | |
| MAZEMaze Therapeutics, Inc. | $1.85B | -1.3% | +545.2% | 95.3% | – | – | – | |
| ZYMEZymeworks Inc. | $1.84B | +0.8% | – | 98.4% | – | – | – | |
| STOKStoke Therapeutics, Inc. | $1.74B | -0.2% | -81.2% | 98.9% | – | – | – | |
| NTLAIntellia Therapeutics, Inc. | $1.38B | +1.6% | -23.1% | -46.5% | – | – | – | |
| 同行中位数 | – | – | 0.0% | 47.6% | 7.8x | 7.0x | 5.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。